Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation

被引：8
|
作者：
Jentzsch, Madlen [1 ]
Grimm, Juliane [1 ]
Bill, Marius [1 ]
Brauer, Dominic [1 ]
Backhaus, Donata [1 ]
Pointner, Rosmarie [1 ]
Goldmann, Karoline [1 ]
Schulz, Julia [1 ]
Niederwieser, Dietger [1 ]
Platzbecker, Uwe [1 ]
Schwind, Sebastian [1 ]
机构：
[1] Leipzig Univ Hosp, Med Clin & Policlin 1, Hematol & Cellular Therapy, Liebigstr 22,Haus 7, D-04103 Leipzig, Germany
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2021年 / 96卷 / 07期
关键词：
D O I：
10.1002/ajh.26179
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E237 / E239
页数：3
相关论文
共 50 条
  • [21] ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation
    Madlen Jentzsch
    Juliane Grimm
    Marius Bill
    Dominic Brauer
    Donata Backhaus
    Karoline Goldmann
    Julia Schulz
    Dietger Niederwieser
    Uwe Platzbecker
    Sebastian Schwind
    Bone Marrow Transplantation, 2021, 56 : 936 - 945
  • [22] Allogeneic stem cell transplantation and minimal residual disease in patients with AML in first complete remission
    Versluis, Jurjen
    Cornelissen, Jan J.
    HEMASPHERE, 2018, 2 : 162 - 164
  • [23] Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice
    Shaffer, Brian C.
    Kebriaei, Partow
    de Lima, Marcos
    Jimenez, Antonio M. Jimenez
    BONE MARROW TRANSPLANTATION, 2025, 60 (02) : 128 - 134
  • [24] NPM1(+) AML PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION IN FIRST OR SECOND REMISSION: MEASURABLE RESIDUAL DISEASE PREDICTS OUTCOME
    Papalexandri, Apostolia
    Dimou-Besikli, Sotiria
    Demosthenous, Christos
    Paphianou, Eleni
    Kika, Fotini
    Panteliadou, Kira
    Spyridis, Nikos
    Boussiou, Zoe
    Kyriakou, Giannis
    Vardi, Anna
    Touloumenidou, Tasoula
    Zerva, Panagiota
    Koutra, Maria Georgia
    Paleta, Angeliki
    Konstantinidou, Georgia
    Vachtsetzi, Lamprini
    Lalayanni, Chrisavgi
    Gavriilaki, Eleni
    Papathanasiou, Maria
    Marvaki, Anastasia
    Syrigou, Antonia
    Karavalakis, Georgios
    Douka, Vasiliki
    Finitsis, Stefanos
    Athanasiadou, Anastasia
    Sakellari, Ioanna
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 468 - 468
  • [25] Quantifying NPM1 measurable residual disease (MRD) in acute myeloid leukemia (AML) patients undergoing allogeneic stem cell transplantation (HSCT): where to draw the line?
    Schwind, S.
    Bischof, L.
    Bill, M.
    Grimm, J.
    Ussmann, J.
    Backhaus, D.
    Brauer, D.
    Herling, M.
    Merz, M.
    Metzeler, K. H.
    Franke, G. -N.
    Vucinic, V.
    Platzbecker, U.
    Jentzsch, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 26 - 26
  • [26] Monosomal Karyotype Predicts Survival In Patients with High Risk AML Undergoing Allogeneic Stem Cell Transplantation
    Middeke, Jan Moritz
    Beelen, Dietrich
    Stadler, Michael
    Baurmann, Herrad
    Bug, Gesine
    Bellos, Frauke
    Mohr, Brigitte
    Birninger, Nicole
    Buchholz, Stefanie
    Schwerdtfeger, Rainer
    Martin, Hans
    Hegenbart, Ute
    Bornhaeuser, Martin
    Ehninger, Gerhard
    Schetelig, Johannes
    BLOOD, 2010, 116 (21) : 1133 - 1134
  • [27] Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation
    Grimm, Juliane
    Jentzsch, Madlen
    Bill, Marius
    Backhaus, Donata
    Brauer, Dominic
    Kuepper, Johannes
    Schulz, Julia
    Franke, Georg-Nikolaus
    Vucinic, Vladan
    Niederwieser, Dietger
    Platzbecker, Uwe
    Schwind, Sebastian
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (10) : 1287 - 1294
  • [28] Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission
    Jentzsch, Madlen
    Bischof, Lara
    Backhaus, Donata
    Brauer, Dominic
    Schulz, Julia
    Franke, Georg-Nikolaus
    Vucinic, Vladan
    Niederwieser, Dietger
    Platzbecker, Uwe
    Schwind, Sebastian
    BLOOD ADVANCES, 2022, 6 (15) : 4570 - 4580
  • [29] A Disease and Stage Risk Grouping System for Patients Undergoing Allogeneic Stem Cell Transplantation
    Armand, Philippe
    Gibson, Christopher J.
    Cutler, Corey
    Ho, Vincent T.
    Koreth, John
    Alyea, Edwin P., III
    Antin, Joseph H.
    Soiffer, Robert J.
    Kim, Haesook T.
    BLOOD, 2011, 118 (21) : 153 - 154
  • [30] Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission
    Pasvolsky, Oren
    Saliba, Rima M.
    Ledesma, Celina
    Popat, Uday R.
    Alousi, Amin
    Olson, Amanda
    Oran, Betul
    Hosing, Chitra
    Bashir, Qaiser
    Qazilbash, Muzaffar H.
    Short, Nicholas J.
    Ravandi, Farhad
    Champlin, Richard
    Shpall, Elizabeth J.
    Kebriaei, Partow
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (02) : E35 - E37
12345